NeuBase Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$33.3M | −$26.6M | −$17.1M | −$25.5M | −$13.9M | −$23.8M |
| Net income | −$33.8M | −$25.4M | −$17.4M | −$26.1M | −$13.2M | −$23.8M |
| Total assets | $32.7M | $64.2M | $34.4M | $12.5M | $11.6M | $27.9M |
| Total liabilities | $9.5M | $10.1M | $3.1M | $2.5M | $724,998 | $5.1M |
| Equity | $23.2M | $54.1M | $31.3M | $10.0M | $10.9M | $22.8M |
| EPS (diluted) | $-1.04 | $-0.93 | $-0.89 | — | — | — |
| Shares out. | 33.0M | 32.7M | 23.2M | 56.5M | 56.5M | 56.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- −145.6%
- Return on assets
- −103.3%
- Return on capital (ROCE)
- −116.8%
- Liabilities / assets
- 29.1%
- Debt / equity
- 0.41×
- Book value / share
- $0.70
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -10.42distress
- Accruals / assets
- −14.6%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Feb 14, 2020
- NT 10-Kmissed a reporting deadline ↗Dec 31, 2019
- NT 10-Kmissed a reporting deadline ↗Dec 31, 2018
- NT 10-Qmissed a reporting deadline ↗May 10, 2017
- NT 10-Qmissed a reporting deadline ↗Feb 9, 2017
- NT 10-Kmissed a reporting deadline ↗Dec 14, 2016
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Symetryx Corp10% owner | Sep 14, 2023 | Sell | 129,108 | $1.44 |
| Symetryx Corp10% owner | Sep 7, 2023 | Sell | 74,852 | $1.80 |
| Symetryx Corp10% owner | Sep 1, 2023 | Buy | 61,076 | $0.98 |
| Stephan Dietrich AOfficer — Founder and CEO | Aug 2, 2023 | Option exercise | 93,234 | $0.02 |
| Branning Todd P.Officer — Chief Financial Officer | Mar 16, 2023 | Grant | 54,200 | $0.00 |
| Stephan Dietrich AOfficer — CEO and Director | Mar 16, 2023 | Grant | 153,000 | $0.00 |
| Stephan Dietrich AOfficer — President and CEO | Feb 13, 2023 | Option exercise | 655,000 | $0.00 |
| Stephan Dietrich AOfficer — CEO | Sep 28, 2022 | Option exercise | 750,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Director / officer change · Other material eventJan 7, 2025
- Modified shareholder rights · Director / officer change · Shareholder voteJun 27, 2024
- Entered a material agreement · Unregistered equity sale · Modified shareholder rights · Amended charter or bylaws · Other material eventMay 31, 2024
- Shareholder voteMay 22, 2024
- Shareholder voteMay 13, 2024
- Delisting / listing-standard noticeMay 3, 2024
- Delisting / listing-standard notice · Other material eventApr 5, 2024
- Other material eventMar 7, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.